Your browser doesn't support javascript.
Short-Term Side Effects and SARS-CoV-2 Infection after COVID-19 Pfizer-BioNTech Vaccine in Children Aged 5-11 Years: An Italian Real-World Study.
Capponi, Martina; Pulvirenti, Federica; Cinicola, Bianca Laura; Brindisi, Giulia; Conti, Maria Giulia; Colaiocco, Giovanni; de Castro, Giovanna; Guido, Cristiana Alessia; Duse, Marzia; Midulla, Fabio; Zicari, Anna Maria; Spalice, Alberto.
  • Capponi M; Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, 00185 Rome, Italy.
  • Pulvirenti F; Reference Centre for Primary Immune Deficiencies, Azienda Ospedaliera Universitaria Policlinico Umberto I, 00161 Rome, Italy.
  • Cinicola BL; Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, 00185 Rome, Italy.
  • Brindisi G; Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.
  • Conti MG; Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, 00185 Rome, Italy.
  • Colaiocco G; Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, 00185 Rome, Italy.
  • de Castro G; Department of Prevention and Public Health, Coordination of Vaccination Activities, Azienda Sanitaria Locale (ASL) Roma 2, 00157 Rome, Italy.
  • Guido CA; Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, 00185 Rome, Italy.
  • Duse M; Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, 00185 Rome, Italy.
  • Midulla F; Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, 00185 Rome, Italy.
  • Zicari AM; Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, 00185 Rome, Italy.
  • Spalice A; Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, 00185 Rome, Italy.
Vaccines (Basel) ; 10(7)2022 Jun 30.
Article in English | MEDLINE | ID: covidwho-1928691
ABSTRACT
Vaccination against COVID-19 is the most effective tool to protect both the individual and the community from this potentially life-threatening infectious disease. Data from phase-3 trials showed that two doses of the BNT162b2 vaccine were safe, immunogenic, and effective against COVID-19 in children aged 5-11 years. However, no surveys in real-life settings have been carried out in this age range. Here, we conducted a cross-sectional study to evaluate the short-term adverse reactions (ARs) and the rate of protection against infection of the BNT162b2 vaccine in children aged 5-11 years by the compilation of two surveillance questionnaires conceived using Google Forms. Five-hundred and ninety one children were included in the analysis. ARs were reported by 68.9% of the children, being mainly local. The incidence of systemic ARs, especially fever, was higher after the second dose. The incidence of infection after completing the immunization accounted for 13.6% of the children. COVID-19 symptoms reported were mild, with the exception of one case of pneumonia. Only 40% of infected participants needed to take medication to relieve symptoms, mostly paracetamol and NSAIDs, and none reported persistent symptoms. The Pfizer-BioNTech vaccine in children aged 5-11 years is safe and well tolerated. The mild clinical course of COVID-19 in immunized children confirmed the favorable risk-benefit ratio, encouraging parents to immunize their children.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid / Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10071056

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid / Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10071056